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Abstract Human exploration of space requires the ability to understand and mitigate risks to crews exposed to the 
conditions associated with such missions. This becomes a greater imperative as we prepare for interplanetary 
expeditions involving humans who will be subjected to long transit periods in microgravity as they travel to a distant 
planet such as Mars, embark and live on the planet's surface for an extended time, and finally, return to the I g 
envirorunent of Earth. We need to know, more defmitively, what the human health, safety, and performance risks are, 
and how to prevent or counteract them throughout all phases of a long duration mission. The Johnson Space Center' s 
Space and Life Sciences Directorate along with the National Space Biomedical Research Institute (NSBRI) have been 
engaged in a strategic planning effort that identifies the most critical risks confronting humans who will venture forth 
on such missions and the types of research and technology efforts required to mitigate and otherwise reduce the 
probability and/or severity of those risks. This paper describes the unique approach used to defme, assess and prioritize 
the risks and presents the results of the assessment with an emphasis on the research and teclmology priorities that will 
help us to meet the challenge of long duration human spaceflight missions. 
RISKY BUSINESS 
The exploration of space with a human presence, particularly expeditions to other planetary surfaces, is an 
inherently risky business. Radiation exposure, inadequate atmosphere and water, extreme temperatures, prolonged 
isolation and confinement within an enclosed environment, and physiological alterations due to micro gravity 
conditions are all potential hazards that can jeopardize any mission at any time. Ensuring the safety, health and well 
being of the crews that embark on such missions requires the ability to both understand and mitigate risk. In fact, in 
some instances, such as radiation exposure, the Agency has a legal responsibility to inform crews of potential risks 
to their health and safety. This makes identifIcation and quantification of the risk, determination of minimally 
acceptable levels of risk, and development of risk reduction solutions, equally important steps. 
Approach 
Approximately three years ago, the Agency ' s lead center for the human elements of spaceflight (the Johnson Space 
Center), along with the National Biomedical Research Institute (NSBRl) (which has the lead role in developing 
countermeasures) initiated an activity to identify the most critical risks confronting extended human spaceflight. 
Two salient factors influenced this activity: first, what is needed to enable a go/no go decision for embarking on 
extended human spaceflight missions; and second, what is needed to address known and potential health, safety and 
performance risks associated with such missions. A unique approach was used to first define and assess those risks, 
and then to prioritize them. This activity was called the Critical Path Roadmap and it represents an opportunity to 
develop and implement a focused and evolving program of research and technology designed from a " risk 
reduction" perspective to prevent or minimize the risks to humans exposed to the space environment. 
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Key Elements of the Critical Pat~ Roadmap 
The elements comprising the Critical Path Roadmap are shown in Figure 1. (Risk is defined as exposure to the space 
environment resulting in dysfunctional physiological or behavioral adaptation, injwy, illness, or loss of life or 
mission objectives. Risk factors represent conditions associated with an increased probability of the occurrence of 
the risk and can operate singly or in combination to contribute to the risk's occurrence. Critical questions 
encompass the key research and technology issues that must be addressed to understand the risk and its resolution. 
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Critical questions lead to specific deliverables and corresponding tasks. Deliverables are specific end-items that can 
be identified, completed, and made available at known dates. Tasks are the specific research and technology 
projects addressing the questions, providing deliverables, and ultimately the risk mitigation requirements. 
Once risks have been identified, characterized and compared, an important step is the evaluation of a range of 
alternative options and selection of outcomes. This is referred to as risk or, costlbenefit analysis (Hohenemser and 
Kasperson, 1982; Swaney, 1997). Decisions concerning resource allocation are based on valuations of what critical 
risks require mitigation, what knowledge is needed to better understand and mitigate the risk to what level of 
acceptability, the development status of the mitigation, an assessment of current tasks associated with the risk and 
critical questions, mission parameters and resources (e.g., available crew time, power and space). 
The Critical Path Roadmap Process 
Informed decisions about risk reduction options are the product of a combination of two interacting' processes -
analysis and deliberation. While there are no set rules or standard operating procedures on how to achieve the right' 
'balance, both are necessary (NRC, 1996). The Critical Path Roadmap utilized an iterative approach that combined 
review, analysis and deliberations at three stages analogous to expanding concentric circles. Each built upon the 
results of the preceding stage and was characterized by a more objective valuation. 
Stage 1: Risk Identification and Characterization 
The context for risk identification was a possible future agency decision to embark on long duration human 
exploration class missions. A group of approximately 25 intramural scientists, engineers, and program managers 
from JSC, familiar with operational aspects of human spaceflight, met weekly for six months to identify the initial 
set of risks. A review of reports from previous advisory committees (e.g., NASA Countermeasure Task Force Final 
Report, 1997; NRC 1997, 1995, 1987; NAC, 1992) was undertaken to help identify risks and critical issues. Risks 
were determined for missions of varying duration (i.e., Shuttle up to 16 days; ISS up to 180 days; Lunar up to 180 or 
more days; and Mars 500+ days). However, a decision was made to focus on "worst case scenario," (Table 1). 
TABLE 1. Mars Design Reference Mission. 
Earth Departure 2014 with Crew of Six 
Transit Out - 161 Days; Return - 154 Days 
Mars Surface Stay 569 Days 
4 G Transitions 1 G to OG; OG to 1/3G; l/3G to OG; OG to 1 G 
High G Loading , 3-5 (TED) G During Aerobraking and Landing 
The resulting list of risks became part of the ensuing discussions during the next several months that further 
combined and refined the list of risks, with the focus on exploration class missions. In addition, a set of criteria to 
characterize the risks was developed and applied. The risk scoring criteria included the following measures: 
• Expected Occurrence of Risk with No Risk Mitigation or Countermeasures Present 
• Expected Occurrence of Risk with Current Countermeasures 
• Severity of Impact on Mission Objectives 
• . Severity of Impact on Crew Health 
• Risk Mitigation Status 
The review and deliberations, at this stage, produced approximately 100 risks across the following 11 disciplines: 
• Advanced Life Support • Human Behavior and Performance 
• Bone Loss • Immunology, Infection and Hematology 
• Cardiovascular Alterations • Muscle Alterations and Atrophy 
• Clinical Capabilities • Neurovestibular Adaptation 
• Environmental Health • Radiation Effects 
• Food and Nutrition 
Stage 2: Further Risk Identification, Characterization and Ranking 
The second stage of the process involved the participation of a diversified group of extramural scientists 
representing the expertise from the newly formed National Space Biomedical Research Institute (NSBRI). In 
January 1998, approximately 20 members of the NSBRI met with the group of JSC intramural scientists in a three-
day workshop to establish discipline risk area teams and to review, define and assess a final set of risks in each 
discipline. Risk assessment included applying the risk scoring criteria and rank-ordering the risks within the 11 
disciplines. The same group developed a core set of critical questions that must be addressed to mitigate the risks. 
In June 1998, the Critical Path Roadmap was presented to all discipline team members (approximately 200 
scientists) of the NSBRI and further refinement of the risks and critical questions continued over the next several 
months. The risks and critical questions were then presented to approximately 300 NASA life scientists at the First 
Biennial Space Biomedical Investigators Workshop held January, 1999 (NASA, 1999). The last step was validation 
of the refined set of risks and critical questions. This was accomplished through a comparison by discipline risk 
area tearns of the issues and recommendations contained in a recent report of the Committee on Space Biology and 
Medicine (NRC, 1998) with the Critical Path Roadmap discipline area risks and critical questions. 
Stage 3: Cross-Risk Prioritization 
Cross-risk prioritization was accomplished with the participation of a small panel of experts comprised of 
individuals who represented management of biomedical research, astronaut health and safety, medical operations, 
and science policy/planning. There was considerable discussion, over several months, on how to prioritize the risks 
and develop a consensus for a categorization that compared the relative importance of risks based on the discipline 
experts' assessment using the risk scoring criteria and the rank-ordering of the risks. Table 2 shows the 
categorization. (Initial comparison was made across the set of biomedical risks, the remaining "engineering system-
,type" risks, such as unsafe food systems and acceptable atmosphere, were subsequently categorized.) 
TABLE2 A . sSlgnment 0 fRi k TIP' .. S . ypes nontIes . 
Demonstrated Serious Suspected Serious Demonstrated Suspected 
Problem Problem Problem Problem 
No Countermeasure I II II or ill ill 
(CM) Concept 
CMConcept 
- No Ground Validation II n norill ill 
CMConcept 
- No Space Verif~ation III ill ill ill 
Effective Operational IV Not applicable IV Not applicable 
CM 
Results 
The process of careful review, analysis and deliberations resulted in a credible, rank-ordered, and prioritized set of 
critical risks that require risk mitigation strategies designed to prevent or reduce risks to within acceptable levels for 
human exploration class missions. This section presents some of the specific results to date. It is important to 
emphasize that while the structure of the Critical Path Roadmap is a static feature, its content is not, and will 
continue to evolve and change as knowledge is obtained both about the risks and their mitigation. 
Risk Ranking and Cross-Risk Prioritization 
The risk identification and characterization resulted in a total of 55 critical risks across the 11 disciplines, 225 
critical questions, and 100 different risk factors. The results of the risk identification, ranking and cross risk 
prioritization are shown in Table 3. (Risk ID refers to the assigned risk identification number.) Approximately 29 
percent of the risks were ranked asa "1," 22 percent were ranked equally as a "2" or "3", and 24 percent of the risks 
were ranked as "4" or more within their respective discipline. 
Table 3 shows the results also for the cross-risk prioritization (Type). Approximately 7 percent (4 risks) were Type 
I risks; 49 percent (27 risks) were Type II risks, and 43 percent (24 risks) were Type III risks. As seen in the table, 
there are no Type IV risks currently. 
TABLE 3. Critical Path Roadmap Risks, Rank, and Risk TypelPriority. 
m Risk Title Rank Type 
I Inability to Maintain Acceptable Atmosphere in Habitable Areas 1 II 
2 Inability to Provide and Recover Potable Water 2 IT 
3 Inadequate Supplies 2 II 
4 Inability to Maintain Thermal Balance in Habitable Areas 3 II 
5 Inability to Adequately Process Solid Wastes 3 II 
6 Inadequate Stowage and Disposal Facilities for Solid and Liquid Trash Generated During Mission 4 II 
7 Inadequate Nutrition (Malnutrition) 1 II 
8 Unsafe Food Systems 2 II 
9 Acceleration of Age-Related Osteoporosis I I 
10 Fractures (Traumatic, Stress, Avulsion & hnpaired Fracture Healing) 2 ill 
11 Injury to Soft Connective Tissue or Joint Cartilage, & Disc Rupture wi or wlo Neurological 3 ill 
Complications . 
12 Renal Stone Formation 4 ill 
13 Occurrence of Serious Cardiac Dysrhythmias 1 II 
14 Impaired Response to Orthostatic Stress 1 II 
15 Diminished Cardiac Function 2 ill 
16 Manifestation of Previously Asymptomatic Cardiovascular Disease 3 ill 
17 Impaired Response to Exercise Stress 4 ill 
18 Human Performance Failure Because of Poor Psychosocial Adaptation 1 I 
19 Human Performance Failure Because Sleep and Circadian Rhythm Problems 2 II 
20 Human Performance Failure Because of Human System Interface Problems & Ineffective Habitat, 3 ill 
Equipment, Design, Etc. 
21 Human Performance Failure Because of Neurobehavioral Dysfunction 4 ill 
22 Infections 1 ill 
23 Carcinogenesis Caused by Immune System Changes 1 ill 
24 Altered Hemodynamics & Cardiovascular Dynamics from Altered Blood Components 1 ill 
25 Altered Wound Healing 2 ill 
26 Altered Host-Microbial Interactions 3 ill 
27 Allergies and Hypersensitivity Reactions 4 ill 
TABLE 3. Critical Path Roadmap Risks, Rank, and Risk,TypelPriority (Continued). 
ID Risk Title Rank Type 
28 Loss of Skeletal Muscle Mass, Strength, and/or Endurance I II 
29 Inability to Adequately Perfonn Tasks Due to Motor Perfonnance, Muscle Endurance, and I II 
Disruption in Structural and Functional Properties of Soft & Hard Connective Tissue 
30 Inability to Sustain Muscle Perfonnance Levels to Meet Demands of Perfonning Activities of 2 II 
Varying Intensities 
31 Propensity to Develop Muscle Injury, Connective Tissue Dysfunction, and Bone Fmctures Due to 3 ill 
Deficiencies in Motor Skill, Muscle Strength and Muscular Fatigue 
32 Impact of Deficits in Skeletal Muscle Structure and Function on Other Systems NR ill 
33 Disorientation and Inability to Perfonn Landing, Egress, or Other Physical Tasks, Especially 1 II 
During/After G-Level Changes 
34 Impaired Neuromuscular Coordination and/or Strength 2 II 
35 Impaired Cognitive and/or Physical Perfonnance Due to Motion Sickness Symptoms or Treatments, 3 ill 
Especially During/After G-Level Changes 
36 Vestibular Contribution to Cardioregulatory Dysfunction 4 ill 
37 Possible Chronic Impairment of Orientation or Balance Function Due to Microgravity or Radiation 5 ill 
38 Carcinogenesis Caused by Radiation 1 I 
39 Damage to Central Nervous System from Radiation Exposure 2 II 
40 Synergistic Effects from Exposure to Radiation, Microgravity and other Spacecraft Environmental 3 II 
Factors 
41 Early or Acute Effects from Radiation Exposure 4 II 
42 Radiation Effects on Fertility, Sterility. and Heredity 5 ill 
43 Trauma and Acute Medical Problems I I 
44 Toxic Exposure 2 II 
45 Altered Pharmacodynamics and Adverse Drug Reactions 3 II 
46 lllness and Ambulatory Health Problems 4 ill 
47 Development and Treatment of Decompression Illness Complicated by Microgravity-Induced 5 ill 
Deconditioning 
48 Difficulty of Rehabilitation Following Landing 6 ill 
49 Post-landing Alterations in Various Systems Resulting in Severe Perfonnance Decrements and NR II 
Injuries 
50 Allergies and Hypersensitivity Reactions from Exposure to the Enclosed Spacecraft & Other 3 II 
Environmental Factors 
51 Inability to Maintain Acceptable Atmosphere in Habitable Areas Due to Environmental Health I II 
Contaminants 
52 Inability to Provide and Recover Potable Water Due to Environmental Health Contaminants 2 II 
53 Inadequate Nutrition Due to Inability to Provide and Maintain a Bioregenemtive System 1 II 
54 Difficulty of Rehabilitation Following Landing Due to Nutritional Deficiencies 3 ill 
55 Human Perfonnance Failure Due to Nutritional Deficiencies 4 II 
Decisionmaking via the Critical Path Roadmap 
It is the intent of the Critical Path Roadmap to provide the foundation for what is needed to ensure that human 
spaceflight, now and in the future, is as safe, productive and healthy as possible (given the constraints imposed on a 
particular mission) regardless of mission duration or destination. As a tool, the Critical Path Roadmap enables the 
decisionmaker to select among the demonstrated or potential problems for harm those that are to be mitigated and to 
what degree. The following set of questions are examples of how the Critical Path Roadmap will be used to help 
guide decisions about selecting research and technology efforts to mitigate the critical risks. 
. • Does the research or technology address a specific Critical Path Roadmap risk? 
• What Type of risk is addressed? Is it a Type I risk? Is more than one risk addressed by the research? 
• What kind of research or teclmology is represented by the effort (i.e., mechanisms/processes, risk 
assessment, risk mitigation, or medical diagnosis and treatment)? 
• Does the research or' technology address a specific critical question? Is more than one question 
addressed? Is it high priority critical question(s)? 
• Does the effort address or provide information about deliverables associated with the critical questions? 
• What level of readiness is the research or technology project? Is it a level that is currently required for the 
risk, critical question, andlor deliverable? 
• Are there existing tasks/projects that currently address this risk, critical question, or deliverable? 
• Is the timeframe for providing the deliverable(s) compatible with the timeline for the risk? 
The extent to which the proposed research or technology effort addresses these questions strengthens the need and 
priority for the specific task. ,The evaluation process is evolving to incorporate changes in the knowledge of the risk 
as well as the status of its mitigation or countermeasure. Known risks without countenneasures (Type I Risks) have 
priority over potential risks regardless of countenneasure status. The next level of priority distinguishes between 
Type II and Type III Risks, and so forth. Throughout the process, there is constant weighing of alternative options 
depending upon the set of benefits and costs associated with the risks and their mitigation. 
The problem of what level to reduce risks to is more difficult. It is often the case that knowledge fully quantifying 
the risk is incomplete. Estimates of the risk's incidence and prevalence are difficult to acquire because of small 
sample sizes, measurement variability; sustained access to spaceflight or ground-based resources, costs, and other 
factors. Qualitative information is often used to evaluate the risk and determine acceptability levels through a 
deliberative process involving expert opinion and discussion (NRC, 1996). Acceptability levels for Critical Path 
Roadmap risks will be determined through review and deliberations of both quantitative and qualitative information. 
. The goal over the next decade is to reduce the 55 critical risks, which currently lack validated countermeasures, to 
minimally acceptable levels thus rendering tllem Type IV risks,' defined as clinically manageable. ' The specific 
objective is to achieve countermeasure identification and validation for one-half of the current risks by the year 
2006, and by 2010, achieve countenneasure identification and validation for the remaining risks. An adequate level 
of funding to support the necessary research and technology, for the development of effective risk reduction and 
validated mitigation, along with continued access to spaceflight and crew time are important assumptions underlying 
such outcomes. 
CONCLUSIONS 
The Critical Path Roadmap provides the foundation and tool to enable the decision as well as the implementation of 
human exploration class missions. It is an integrated, cross-disciplinary strategy to characterize, assess, understand, 
mitigate and manage the risks associated with long-term exposure to the space environment within overall resource 
considerations. Its success is built upon several principles. 
Rigorous Analyses & Deliberations. Understanding risk is an impo~t component of infonned decisionmaking 
whether the subject is public health policy, medical treatment, or human spaceflight. A degree of uncertainty is an 
inevitable part of the process. The presence of scientific uncertainty, different values, and interpretive judgement 
can influence the outcome (lOM, 1995; NRC, 1996). Successful decisionmaking that results in risk prevention or 
reduction requires rigorous analyses and deliberations (NRC, 1996). The Critical Path Roadmap is a product of 
both. Risk analysis was provided by discipline experts who reviewed the scientific evidence about the risks and 
debated relative importance among the set of risks within their disciplines. Validation was established from a 
comprehensive comparison of the risks, critic~l questions and priorities with the issues and recommendations of a 
recent advisory report (NRC, 1998). The cross-risk prioritization was derived from a group of experts who reviewed 
the results of the discipline-based risk analysis and developed decision-rules for comparing, categorizing, and 
prioritizing the relative importance among the risks. 
Communication & Access. Communication of the Critical Path Roadmap and access to its content is important for 
its success. Success is defined as eliminating or reducing the critical risks by allocating necessary resources to 
research and technology efforts focused on the identified risks, their questions, and associated risk mitigations and 
couritenneasures. Providing the Critical Path Roadmap content to potential investigators increases the probability of 
delivering effective risk mitigations. Several sources have been employed to achieve this goal. The first is a 
dedicated user-friendly web site that contains the Critical Path Roadmap content and will incorporate changes as the 
knowledge base evolves. Second, a base-lined document will be available in early 2000 containing the elements of 
the Critical Path Roadmap. In addition, a configuration control board will continue the deliberative process and 
provide approval and documentation of subsequent changes as the Critical Path Roadmap evolves. 
Management, Decisionmaking & Credibility. The interrelationship among the risks and their mitigation requires 
coordinated planning, execution and management of resources. The development of timelines for achieving risk 
mitigation is an important management and decisionmaking tool. One of the key components of the Critical Path 
Roadmap is the development of risk-based timelines that will integrate across the critical questions, tasks and 
deliverables related to a risk, or set of risks. Continued review of the Critical Path Roadmap by both management 
and advisory committees will provide a realistic sounding board to evaluate alternative options for risk prevention or 
reduction, to avoid missed opportunities and poor decisionmaking, as well as a means for continued credibility. 
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